CStone Pharmaceuticals (PH4) Stock Overview
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PH4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.57 |
| 52 Week High | HK$1.35 |
| 52 Week Low | HK$0.45 |
| Beta | 0.25 |
| 1 Month Change | 14.56% |
| 3 Month Change | -47.24% |
| 1 Year Change | -0.90% |
| 3 Year Change | 95.54% |
| 5 Year Change | -70.01% |
| Change since IPO | -60.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| PH4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -2.2% | -2.5% |
| 1Y | -0.9% | 13.8% | -0.6% |
Return vs Industry: PH4 underperformed the German Biotechs industry which returned 13.8% over the past year.
Return vs Market: PH4 matched the German Market which returned -0.6% over the past year.
Price Volatility
| PH4 volatility | |
|---|---|
| PH4 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: PH4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PH4's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 136 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili.
CStone Pharmaceuticals Fundamentals Summary
| PH4 fundamental statistics | |
|---|---|
| Market cap | €942.97m |
| Earnings (TTM) | -€56.50m |
| Revenue (TTM) | €34.85m |
Is PH4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PH4 income statement (TTM) | |
|---|---|
| Revenue | CN¥269.58m |
| Cost of Revenue | CN¥218.34m |
| Gross Profit | CN¥51.25m |
| Other Expenses | CN¥488.25m |
| Earnings | -CN¥437.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 19.01% |
| Net Profit Margin | -162.10% |
| Debt/Equity Ratio | 55.5% |
How did PH4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 03:19 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CStone Pharmaceuticals is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| null null | Guoyuan Securities (HK) Ltd |
| Hanyang Huang | Industrial Securities Co. Ltd. |